Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
12,214
archived clinical trials in
Women's Studies

Early Elimination of Premature Ventricular Contractions in Heart Failure
EVAC-HF is a Prospective, Multi-center, Randomized Study to Compare the Effects on LV Systolic Function Following Radiofrequency Catheter Ablation of Frequent Premature Ventricular Contraction With Optimized Medical Therapy Alone.
Status: Enrolling
Updated:  6/20/2017
University of Michigan
mi
from
Ann Arbor, MI
Early Elimination of Premature Ventricular Contractions in Heart Failure
EVAC-HF is a Prospective, Multi-center, Randomized Study to Compare the Effects on LV Systolic Function Following Radiofrequency Catheter Ablation of Frequent Premature Ventricular Contraction With Optimized Medical Therapy Alone.
Status: Enrolling
Updated: 6/20/2017
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Early Elimination of Premature Ventricular Contractions in Heart Failure
EVAC-HF is a Prospective, Multi-center, Randomized Study to Compare the Effects on LV Systolic Function Following Radiofrequency Catheter Ablation of Frequent Premature Ventricular Contraction With Optimized Medical Therapy Alone.
Status: Enrolling
Updated:  6/20/2017
Ohio State University
mi
from
Columbus, OH
Early Elimination of Premature Ventricular Contractions in Heart Failure
EVAC-HF is a Prospective, Multi-center, Randomized Study to Compare the Effects on LV Systolic Function Following Radiofrequency Catheter Ablation of Frequent Premature Ventricular Contraction With Optimized Medical Therapy Alone.
Status: Enrolling
Updated: 6/20/2017
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Early Elimination of Premature Ventricular Contractions in Heart Failure
EVAC-HF is a Prospective, Multi-center, Randomized Study to Compare the Effects on LV Systolic Function Following Radiofrequency Catheter Ablation of Frequent Premature Ventricular Contraction With Optimized Medical Therapy Alone.
Status: Enrolling
Updated:  6/20/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Early Elimination of Premature Ventricular Contractions in Heart Failure
EVAC-HF is a Prospective, Multi-center, Randomized Study to Compare the Effects on LV Systolic Function Following Radiofrequency Catheter Ablation of Frequent Premature Ventricular Contraction With Optimized Medical Therapy Alone.
Status: Enrolling
Updated: 6/20/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Early Elimination of Premature Ventricular Contractions in Heart Failure
EVAC-HF is a Prospective, Multi-center, Randomized Study to Compare the Effects on LV Systolic Function Following Radiofrequency Catheter Ablation of Frequent Premature Ventricular Contraction With Optimized Medical Therapy Alone.
Status: Enrolling
Updated:  6/20/2017
University of Quebec
mi
from
Sainte-Foy,
Early Elimination of Premature Ventricular Contractions in Heart Failure
EVAC-HF is a Prospective, Multi-center, Randomized Study to Compare the Effects on LV Systolic Function Following Radiofrequency Catheter Ablation of Frequent Premature Ventricular Contraction With Optimized Medical Therapy Alone.
Status: Enrolling
Updated: 6/20/2017
University of Quebec
mi
from
Sainte-Foy,
Click here to add this to my saved trials
Genomic Sequencing in Acutely Ill Neonates
Prospective Randomized Trial of the Clinical Utility of Rapid Next Generation Sequencing in Acutely Ill Neonates
Status: Enrolling
Updated:  6/22/2017
Children's Mercy Hospital
mi
from
Kansas City, MO
Genomic Sequencing in Acutely Ill Neonates
Prospective Randomized Trial of the Clinical Utility of Rapid Next Generation Sequencing in Acutely Ill Neonates
Status: Enrolling
Updated: 6/22/2017
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
Adolescents Born Preterm; Nurtured Beginnings
Adolescents Born Preterm: Nurtured Beginnings
Status: Enrolling
Updated:  6/27/2017
Children's Hospital Boston
mi
from
Boston, MA
Adolescents Born Preterm; Nurtured Beginnings
Adolescents Born Preterm: Nurtured Beginnings
Status: Enrolling
Updated: 6/27/2017
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Effect of Feedings on Caffeine in Premature Infants
Effect of Feedings on Caffeine Pharmacokinetics and Metabolism in Premature Infants
Status: Enrolling
Updated:  6/27/2017
North Carolina Children's Hospital
mi
from
Chapel Hill, NC
Effect of Feedings on Caffeine in Premature Infants
Effect of Feedings on Caffeine Pharmacokinetics and Metabolism in Premature Infants
Status: Enrolling
Updated: 6/27/2017
North Carolina Children's Hospital
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Effect of Feedings on Caffeine in Premature Infants
Effect of Feedings on Caffeine Pharmacokinetics and Metabolism in Premature Infants
Status: Enrolling
Updated:  6/27/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Effect of Feedings on Caffeine in Premature Infants
Effect of Feedings on Caffeine Pharmacokinetics and Metabolism in Premature Infants
Status: Enrolling
Updated: 6/27/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Clinical and Biological Outcomes of Human Milk and Formula Intake After Gastroschisis Repair
Clinical and Biological Outcomes of Human Milk and Formula Intake After Gastroschisis Repair
Status: Enrolling
Updated:  6/27/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Clinical and Biological Outcomes of Human Milk and Formula Intake After Gastroschisis Repair
Clinical and Biological Outcomes of Human Milk and Formula Intake After Gastroschisis Repair
Status: Enrolling
Updated: 6/27/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Effect of Exercise and Wellness Interventions on Preventing Postpartum Depression
Effect of Exercise and Wellness Interventions on Preventing Postpartum Depression.
Status: Enrolling
Updated:  6/28/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Effect of Exercise and Wellness Interventions on Preventing Postpartum Depression
Effect of Exercise and Wellness Interventions on Preventing Postpartum Depression.
Status: Enrolling
Updated: 6/28/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Placental Growth and Adverse Pregnancy Outcomes
Placental Growth and Maternal Serum Biomarkers in the Prediction of Adverse Pregnancy Outcome
Status: Enrolling
Updated:  7/17/2017
University of Pennsylvania Health System
mi
from
Philadelphia, PA
Placental Growth and Adverse Pregnancy Outcomes
Placental Growth and Maternal Serum Biomarkers in the Prediction of Adverse Pregnancy Outcome
Status: Enrolling
Updated: 7/17/2017
University of Pennsylvania Health System
mi
from
Philadelphia, PA
Click here to add this to my saved trials
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase I Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant PoIylCLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML
Status: Enrolling
Updated:  7/20/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase I Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant PoIylCLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML
Status: Enrolling
Updated: 7/20/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Permissive Hypercapnia and Brain Development in Premature Infants
Status: Enrolling
Updated:  7/24/2017
Arkansas Children's Hospital
mi
from
Little Rock, AR
Permissive Hypercapnia and Brain Development in Premature Infants
Status: Enrolling
Updated: 7/24/2017
Arkansas Children's Hospital
mi
from
Little Rock, AR
Click here to add this to my saved trials
Vaginal Diazepam for the Treatment of Female Pelvic Pain
Intravaginal Diazepam for the Treatment of Pelvic Pain Among Women With Pelvic Floor Hypertonic Disorder: a Double Blind, Randomized, Placebo Controlled Trial
Status: Enrolling
Updated:  7/25/2017
Missouri Center for Female Continence and Advanced Pelvic Surgery, University of Missouri Health System
mi
from
Columbia, MO
Vaginal Diazepam for the Treatment of Female Pelvic Pain
Intravaginal Diazepam for the Treatment of Pelvic Pain Among Women With Pelvic Floor Hypertonic Disorder: a Double Blind, Randomized, Placebo Controlled Trial
Status: Enrolling
Updated: 7/25/2017
Missouri Center for Female Continence and Advanced Pelvic Surgery, University of Missouri Health System
mi
from
Columbia, MO
Click here to add this to my saved trials
Post Market Surveillance to Evaluate the Effectiveness the Polaris Deformity Spinal System
A Post Market Surveillance Validation to Evaluate the Effectiveness of the Following System: Polaris Deformity Spinal System
Status: Enrolling
Updated:  8/1/2017
Orthopedics for Kids, PC
mi
from
Birmingham, AL
Post Market Surveillance to Evaluate the Effectiveness the Polaris Deformity Spinal System
A Post Market Surveillance Validation to Evaluate the Effectiveness of the Following System: Polaris Deformity Spinal System
Status: Enrolling
Updated: 8/1/2017
Orthopedics for Kids, PC
mi
from
Birmingham, AL
Click here to add this to my saved trials
Post Market Surveillance to Evaluate the Effectiveness the Polaris Deformity Spinal System
A Post Market Surveillance Validation to Evaluate the Effectiveness of the Following System: Polaris Deformity Spinal System
Status: Enrolling
Updated:  8/1/2017
Loma Linda University
mi
from
Loma Linda, CA
Post Market Surveillance to Evaluate the Effectiveness the Polaris Deformity Spinal System
A Post Market Surveillance Validation to Evaluate the Effectiveness of the Following System: Polaris Deformity Spinal System
Status: Enrolling
Updated: 8/1/2017
Loma Linda University
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Post Market Surveillance to Evaluate the Effectiveness the Polaris Deformity Spinal System
A Post Market Surveillance Validation to Evaluate the Effectiveness of the Following System: Polaris Deformity Spinal System
Status: Enrolling
Updated:  8/1/2017
Children's Orthopedics of Atlanta
mi
from
Atlanta, GA
Post Market Surveillance to Evaluate the Effectiveness the Polaris Deformity Spinal System
A Post Market Surveillance Validation to Evaluate the Effectiveness of the Following System: Polaris Deformity Spinal System
Status: Enrolling
Updated: 8/1/2017
Children's Orthopedics of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Post Market Surveillance to Evaluate the Effectiveness the Polaris Deformity Spinal System
A Post Market Surveillance Validation to Evaluate the Effectiveness of the Following System: Polaris Deformity Spinal System
Status: Enrolling
Updated:  8/1/2017
Orthopedics Indianapolis, P.C.
mi
from
Indianapolis, IN
Post Market Surveillance to Evaluate the Effectiveness the Polaris Deformity Spinal System
A Post Market Surveillance Validation to Evaluate the Effectiveness of the Following System: Polaris Deformity Spinal System
Status: Enrolling
Updated: 8/1/2017
Orthopedics Indianapolis, P.C.
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Post Market Surveillance to Evaluate the Effectiveness the Polaris Deformity Spinal System
A Post Market Surveillance Validation to Evaluate the Effectiveness of the Following System: Polaris Deformity Spinal System
Status: Enrolling
Updated:  8/1/2017
Rochester Hills Orthopedics
mi
from
Rochester Hills, MI
Post Market Surveillance to Evaluate the Effectiveness the Polaris Deformity Spinal System
A Post Market Surveillance Validation to Evaluate the Effectiveness of the Following System: Polaris Deformity Spinal System
Status: Enrolling
Updated: 8/1/2017
Rochester Hills Orthopedics
mi
from
Rochester Hills, MI
Click here to add this to my saved trials
Post Market Surveillance to Evaluate the Effectiveness the Polaris Deformity Spinal System
A Post Market Surveillance Validation to Evaluate the Effectiveness of the Following System: Polaris Deformity Spinal System
Status: Enrolling
Updated:  8/1/2017
Torre Auxillo Mutuo
mi
from
San Juan,
Post Market Surveillance to Evaluate the Effectiveness the Polaris Deformity Spinal System
A Post Market Surveillance Validation to Evaluate the Effectiveness of the Following System: Polaris Deformity Spinal System
Status: Enrolling
Updated: 8/1/2017
Torre Auxillo Mutuo
mi
from
San Juan,
Click here to add this to my saved trials
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase I Study of Decitabine, Vorinostat, and Cytarabine in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/1/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase I Study of Decitabine, Vorinostat, and Cytarabine in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/1/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase I Study of Decitabine, Vorinostat, and Cytarabine in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/1/2017
M D Anderson Cancer Center
mi
from
Houston, TX
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase I Study of Decitabine, Vorinostat, and Cytarabine in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/1/2017
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Mobile App for Prenatal Care to Reduce Visits and Improve Satisfaction Study
Effectiveness of a Mobile App for Prenatal Care to Safely Reduce In-Person Visits and Improve Patient Satisfaction: Study Protocol for a Multicenter Prospective Quasi-Randomized Trial
Status: Enrolling
Updated:  8/1/2017
George Washington University Hospital
mi
from
Washington, D.C.,
Mobile App for Prenatal Care to Reduce Visits and Improve Satisfaction Study
Effectiveness of a Mobile App for Prenatal Care to Safely Reduce In-Person Visits and Improve Patient Satisfaction: Study Protocol for a Multicenter Prospective Quasi-Randomized Trial
Status: Enrolling
Updated: 8/1/2017
George Washington University Hospital
mi
from
Washington, D.C.,
Click here to add this to my saved trials
The NICHD Fetal Growth Study: Twin Gestations
NICHD Fetal Growth Study: Twin Gestations
Status: Enrolling
Updated:  8/2/2017
University of California-Long Beach
mi
from
Long Beach, CA
The NICHD Fetal Growth Study: Twin Gestations
NICHD Fetal Growth Study: Twin Gestations
Status: Enrolling
Updated: 8/2/2017
University of California-Long Beach
mi
from
Long Beach, CA
Click here to add this to my saved trials
The NICHD Fetal Growth Study: Twin Gestations
NICHD Fetal Growth Study: Twin Gestations
Status: Enrolling
Updated:  8/2/2017
University of California, Irvine Medical Center
mi
from
Orange, CA
The NICHD Fetal Growth Study: Twin Gestations
NICHD Fetal Growth Study: Twin Gestations
Status: Enrolling
Updated: 8/2/2017
University of California, Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
The NICHD Fetal Growth Study: Twin Gestations
NICHD Fetal Growth Study: Twin Gestations
Status: Enrolling
Updated:  8/2/2017
Christiana Care Health Services, Inc
mi
from
Newark, DE
The NICHD Fetal Growth Study: Twin Gestations
NICHD Fetal Growth Study: Twin Gestations
Status: Enrolling
Updated: 8/2/2017
Christiana Care Health Services, Inc
mi
from
Newark, DE
Click here to add this to my saved trials
The NICHD Fetal Growth Study: Twin Gestations
NICHD Fetal Growth Study: Twin Gestations
Status: Enrolling
Updated:  8/2/2017
National Institute of Child Health and Human Development (NICHD), 9000 Rockville
mi
from
Bethesda, MD
The NICHD Fetal Growth Study: Twin Gestations
NICHD Fetal Growth Study: Twin Gestations
Status: Enrolling
Updated: 8/2/2017
National Institute of Child Health and Human Development (NICHD), 9000 Rockville
mi
from
Bethesda, MD
Click here to add this to my saved trials
The NICHD Fetal Growth Study: Twin Gestations
NICHD Fetal Growth Study: Twin Gestations
Status: Enrolling
Updated:  8/2/2017
Columbia University
mi
from
New York, NY
The NICHD Fetal Growth Study: Twin Gestations
NICHD Fetal Growth Study: Twin Gestations
Status: Enrolling
Updated: 8/2/2017
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
The NICHD Fetal Growth Study: Twin Gestations
NICHD Fetal Growth Study: Twin Gestations
Status: Enrolling
Updated:  8/2/2017
Women and Infants
mi
from
Providence, RI
The NICHD Fetal Growth Study: Twin Gestations
NICHD Fetal Growth Study: Twin Gestations
Status: Enrolling
Updated: 8/2/2017
Women and Infants
mi
from
Providence, RI
Click here to add this to my saved trials
The NICHD Fetal Growth Study: Twin Gestations
NICHD Fetal Growth Study: Twin Gestations
Status: Enrolling
Updated:  8/2/2017
Medical University of S. Carolina
mi
from
Charleston, SC
The NICHD Fetal Growth Study: Twin Gestations
NICHD Fetal Growth Study: Twin Gestations
Status: Enrolling
Updated: 8/2/2017
Medical University of S. Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
The NICHD Fetal Growth Study: Twin Gestations
NICHD Fetal Growth Study: Twin Gestations
Status: Enrolling
Updated:  8/2/2017
University of Alabama
mi
from
Birmingham, AL
The NICHD Fetal Growth Study: Twin Gestations
NICHD Fetal Growth Study: Twin Gestations
Status: Enrolling
Updated: 8/2/2017
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
The NICHD Fetal Growth Study: Twin Gestations
NICHD Fetal Growth Study: Twin Gestations
Status: Enrolling
Updated:  8/2/2017
Northwestern University
mi
from
Chicago, IL
The NICHD Fetal Growth Study: Twin Gestations
NICHD Fetal Growth Study: Twin Gestations
Status: Enrolling
Updated: 8/2/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
University of Mississippi Medical Center
mi
from
Jackson, MS
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Singing River Hospital
mi
from
Pascagoula, MS
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Singing River Hospital
mi
from
Pascagoula, MS
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Riverside Methodist Hospital
mi
from
Columbus, OH
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Riverside Methodist Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Medical University of South Carolina
mi
from
Charleston, SC
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Lyndon Baines Johnson General Hospital
mi
from
Houston, TX
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Lyndon Baines Johnson General Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Women and Infants Hospital
mi
from
Providence, RI
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials